Asthma drug trial for kids halted early
NCT ID NCT03650400
Summary
This study aimed to test how a chewable asthma drug called fevipiprant is processed by the body in children aged 6 to 12. It was a short, 8-day trial to find the right dose for kids for future studies. However, the drug's development program was discontinued, so this study was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Minneapolis, Minnesota, 55402, United States
-
Novartis Investigative Site
Columbia, Missouri, 65203, United States
-
Novartis Investigative Site
Tulsa, Oklahoma, 74136, United States
-
Novartis Investigative Site
Boerne, Texas, 78006, United States
-
Novartis Investigative Site
El Paso, Texas, 79903, United States
-
Novartis Investigative Site
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.